Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

Health Services Research & Development

Go to the ORD website
Go to the QUERI website

HSR&D Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Calcium Channel Blockers and Risk of Lymphedema among Breast Cancer Patients: Nested Case-Control Study.

Stolarz AJ, Lakkad M, Klimberg VS, Painter JT. Calcium Channel Blockers and Risk of Lymphedema among Breast Cancer Patients: Nested Case-Control Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2019 Nov 1; 28(11):1809-1815.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.
   Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions



Abstract:

BACKGROUND: To assess the risk of lymphedema associated with the use of calcium channel blockers (CCB) among breast cancer patients. METHODS: A nested case-control study of adult female breast cancer patients receiving an antihypertensive agent was conducted using administrative claims data between 2007 and 2015. Cases were patients with lymphedema who were matched to 5 controls based on nest entry date (±180 days), age (±5 years), number of hypertensive drug classes, Charlson Comorbidity Index (CCI), thiazide exposure, and insurance type. Exposure to CCBs and covariates was identified in the 180-day period prior to event date. Conditional logistic regression was used to assess the impact of exposure among cases and controls. RESULTS: A total of 717 cases and 1,681 matched controls were identified. After matching on baseline characteristics, mastectomy (7.8% vs. 4.8%; = 0.0039), exposure to radiotherapy (27.1% vs. 21.7%; = 0.0046), taxane-based chemotherapy (11.7% vs. 7.4%; = 0.0007), anthracycline-based chemotherapy (6.0% vs. 3.6%; = 0.0073), CCB use (28.3% vs. 23.3%; = 0.0087), and CCI (19.8% vs. 12.7%; < 0.0001; score of 4 or above) were all higher in cases during the 180 days prior to the event date. In the adjusted analysis, CCB exposure was significantly associated with increased risk of lymphedema (OR = 1.320; 95% confidence interval, 1.003-1.737). CONCLUSIONS: CCB use was significantly associated with the development of lymphedema in breast cancer patients. IMPACT: CCBs should be avoided or used with caution in breast cancer patients to reduce the risk for developing lymphedema.





Questions about the HSR&D website? Email the Web Team.

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.